

FORM 8 AMENDMENT

The (Form 8/8.3/8.5) – Futura Medical's announcement released on 17 September 2026 at 07:00 under RNS No 1032V has been amended.

Amendments are identified with an asterisk (*).

The full amended text is shown below.

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:	Futura Medical plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i>	Futura Medical plc
(d) Is the discloser the offeror or the offeree?	OFFEREE
(e) Date position held: <i>The latest practicable date prior to the disclosure</i>	16 September 2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	Ordinary shares of 0.2 pence each			
	Interests		Short positions	
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil	0	Nil	0
(2) Cash-settled derivatives:	Nil	0	Nil	0
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	0	Nil	0
TOTAL:	Nil	0	Nil	0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	None
Details, including nature of the rights concerned and relevant percentages:	None

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

- a) Interests in Futura Medical plc's ordinary shares in which the directors of Futura Medical plc's are interested:

Name	Number of ordinary shares held	Percentage of total issued share capital (to two decimal places)
Alexander Duggan	5,000,000	0.78
Angela Hildreth	642,857	0.10
Kenneth James	799,501	0.13
Andrew Unitt	68,717	0.01
Roy Davis	40,295	0.01

- b) Options and awards held by directors of the Futura Medical plc:

Name	Share plan	No of ordinary shares under options / awards	Date of award	Exercise price (per share)	Vesting date	Expiry date
Alexander Duggan	26 LTIP	29,056,032	15 January 26	0.2p	15 January 2027*	15 July 2027
Angela Hildreth	26 LTIP	11,622,413	15 January 2026	*0.2p	15 January 2027*	15 July 2027
Angela Hildreth	LTIP 1	472,340	7 December 22	0.2p	10 January 23	6 December 32
Angela Hildreth	LTIP 2	1,267,742	10 October 23	0.2p	10 October 23	30 October 23
Angela Hildreth	Tranche 16	200,000	17 September 19	31p	1 October 21	30 September 26

Angela Hildreth	Tranche 17	200,000	21 September 20	15.5p	1 October 22	30 September 27
Angela Hildreth	Tranche 18	264,000	5 October 21	37.90p	1 October 23	30 September 28
Angela Hildreth	Tranche 20	132,000	14 September 22	45p	1 October 25	30 September 30
Angela Hildreth	Tranche 21	264,000	6 April 23	43.60p	1 April 26	31 March 33
Angela Hildreth	Tranche 22	280,000	19 April 24	35.5p	1 April 27	31 March 34
Ken James	26 LTIP	11,622,413	15 January 2026	*0.2p	15 January 2027*	15 July 2027
Ken James	LTIP 1	509,225	7 December 22	0.2p	10 January 23	6 December 32
Kenneth James	LTIP 2	1,366,728	10 October 23	0.2p	10 October 23	30 October 23
Kenneth James	Tranche 16	200,000	17 September 19	31p	1 October 21	30 September 26
Kenneth James	Tranche 17	240,000	21 September 20	15.5p	1 October 22	30 September 27
Kenneth James	Tranche 18	264,000	5 October 21	37.90p	1 October 23	30 September 28
Kenneth James	Tranche 20	132,000	14 September 22	45p	1 October 25	30 September 30
Kenneth James	Tranche 21	264,000	6 April 23	43.60p	1 April 26	31 March 33
Kenneth James	Tranche 22	280,000	19 April 24	35.5p	1 April 27	31 March 34
Andrew Unitt	N/A	N/A	N/A	N/A	N/A	N/A
Roy Davis	N/A	N/A	N/A	N/A	N/A	N/A

**The extent to which awards under the 26 LTIP vest is subject to the achievement of performance targets with those options expiring 6 months from that date.*

c) Interests of connected advisers:

Name	Number of ordinary shares held	Percentage of total issued share capital (to two decimal places)
Benjamin Turner, James Pope & close relatives**	21,749,999	3.40

d) Warrants (exercisable in return for one Ordinary Share each) held over Futura Medical plc's Ordinary Shares ("Warrants") by persons acting in concert (connected adviser) with Futura Medical plc

Name	Date of grant	Expiry date	Number of Warrants held	Exercise Price per Warrant
Turner Pope Investments (TPI) Limited	4 December 2025	4 December 2030	34,375,000	1p

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: <i>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"</i>
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: <i>If there are no such agreements, arrangements or understandings, state "none"</i>
None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	17 September 2026
Contact name:	Angela Hildreth
Telephone number:	01483 685670

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.